Novacyt (LON:NCYT) Releases Quarterly Earnings Results

Novacyt (LON:NCYT) released its quarterly earnings data on Wednesday. The company reported GBX (8) EPS for the quarter, Digital Look Earnings reports. Novacyt had a negative return on equity of 96.44% and a negative net margin of 103.08%.

Novacyt Stock Performance

Novacyt stock traded down GBX 0.90 during midday trading on Wednesday, reaching GBX 42. 60,649 shares of the company traded hands, compared to its average volume of 175,063. Novacyt has a 12 month low of GBX 26.60 and a 12 month high of GBX 86. The company has a debt-to-equity ratio of 44.74, a current ratio of 4.74 and a quick ratio of 4.46. The business has a 50 day moving average of GBX 41.77 and a two-hundred day moving average of GBX 39.06. The firm has a market capitalization of £30.45 million, a price-to-earnings ratio of -1.31 and a beta of 1.11.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.